1
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
2
Country: Israel | Funding: $123.8M
Sight Diagnostics aims to bring affordable, scalable and accurate blood diagnostics to the point-of-care, thereby accelerating better patient outcomes and improving healthcare for all. Sight has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its proprietary machine-vision technology.
Sight Diagnostics aims to bring affordable, scalable and accurate blood diagnostics to the point-of-care, thereby accelerating better patient outcomes and improving healthcare for all. Sight has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its proprietary machine-vision technology.
3
Country: USA | Funding: $100M
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
4
Country: Netherlands | Funding: $17.1M
Landcent is accelerating the fight against infectious diseases of poverty through affordable, scalable and safe technologies.
Landcent is accelerating the fight against infectious diseases of poverty through affordable, scalable and safe technologies.
5
Country: India
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
6
Country: Australia
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
